Sclerosis

Anokion Announces Leadership Team Expansion to Support Advancement of Clinical-Stage Autoimmune Pipeline

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, National, Villanova University, Marketing, University, Research, Alexion, Multiple sclerosis, Johnson & Johnson, Shire, Nephrology, CRA International, Spark Therapeutics, Biogen, Therapy, Patient, Immune tolerance, Biology, Viral disease, Autoimmune disease, Regiment University of Witwatersrand, Genzyme, Acquisition, Dimension, Shire (pharmaceutical company), Sclerosis, Microbiology, Industry, Degenerative disease, Institute, Psychology, Abbott, George Mason University, National Jewish Health, Dartmouth College, Health, Haemophilia, Pharmacy, Denison University, Pfizer, Foundation for the National Institutes of Health, Head, Doctor of Philosophy, Liver, Pharmaceutical industry, Management, Daimler Freeline, EU

Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced appointments to the companys leadership team to support the continued advancement of its pipeline, including its clinical-stage programs, KAN-101 and ANK-700.

Key Points: 
  • Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced appointments to the companys leadership team to support the continued advancement of its pipeline, including its clinical-stage programs, KAN-101 and ANK-700.
  • Dr. Long brings extensive industry and clinical experience to Anokion, with a proven track record developing therapies, which include five successful regulatory approvals over her career.
  • She has held roles in clinical & translational development at Anokion since 2019, most recently as vice president, clinical & translational development.
  • The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes.

XRHealth Publishes New Study Demonstrating that Virtual Reality Technology is Viable in Treating Upper Limb Dysfunction in Multiple Sclerosis Patients

Retrieved on: 
Wednesday, September 28, 2022
Multiple sclerosis, Tremor, Movement, FDA, Research, Sclerosis, Muscle weakness, Health, Patient, MS, CEO, Technology, CE, XR, Rancho Los Amigos National Rehabilitation Center, Extended reality, Pain management, Virtual reality, Rehabilitation, Hospital, VR, Medical device, Metaverse

BOSTON, Sept. 28, 2022 /PRNewswire/ -- XRHealth, the leading healthcare platform in the metaverse, announces today they published a new study in JMIR Serious Games that demonstrates that virtual reality technology is viable in treating upper limb dysfunction in multiple sclerosis patients. The research highlights that XRHealth software is safe, reliable, and engaging for patients while improving overall upper limb functionality.

Key Points: 
  • The research highlights that XRHealth software is safe, reliable, and engaging for patients while improving overall upper limb functionality.
  • Multiple Sclerosis is a neurological and disabling disease that effects 2.8 million people worldwide and causes upper limb dysfunction in 50-76% percent of patients.
  • The physical therapist treating the patients reported that the virtual reality training would be viable for 86.67% of patients.
  • "The study proves that virtual reality rehabilitation is safe and engaging for MS patients," says Eran Orr, CEO of XRHealth.

Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)

Retrieved on: 
Wednesday, September 21, 2022
Multiple sclerosis, Safety, Injection, Department, Chief executive officer, Mount Sinai, MAPI, Sclerosis, Principal, Compliance, LCM, RMS, Icahn School of Medicine at Mount Sinai, Partnership, Glatiramer acetate, PPMS, Diabetes, Patient, MS, GA, Patient satisfaction, API, CEO, ARR, Department of Neurology, Xuanwu hospital, Medicine, NASDAQ, NESS, Â, GLOBE, IM, Patent, Pharmaceutical industry, Fine chemical, Viatris

The positive top-line efficacy results from the GA Depot 40 mg Phase III trial are an exciting step forward in our long-standing commitment to supporting the needs of the multiple sclerosis community.

Key Points: 
  • The positive top-line efficacy results from the GA Depot 40 mg Phase III trial are an exciting step forward in our long-standing commitment to supporting the needs of the multiple sclerosis community.
  • GA Depot is intended to be used for treatment of Relapsing forms of Multiple Sclerosis (RMS).
  • Mapi Pharma partnered with Viatris (NASDAQ: VTRS) for GA Depot in an agreement under which Viatris was granted an exclusive license to commercialize the GA Depot injection product for relapsing forms of multiple sclerosis.
  • Mapi Pharma was founded by Ehud Marom who serves as Chairman & CEO of Mapi Pharma and Stem Cell Medicine.

Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab

Retrieved on: 
Tuesday, September 20, 2022
Autoimmunity, Safety, Trial of the century, Rest, IV, COVID-19, Cytokine, Sclerosis, Principal, Expanded Disability Status Scale, Immunotherapy, Program, Patient, PET, EDSS, Crohn's disease, Neurology, Technology, Mab, BWH, Degenerative disease, SPMS, Inflammation, GLOBE, Pharmaceutical industry, Medical imaging, Regulatory T cell, Foralumab, Foralumab, Brigham

On September 12th, 2022, this patient had walked 100 meters without a cane or need for rest.

Key Points: 
  • On September 12th, 2022, this patient had walked 100 meters without a cane or need for rest.
  • SPMS represents an advanced stage of multiple sclerosis with few treatment options and creates a severe burden on patients.
  • Once a day treatment for 10 consecutive days with intranasal foralumab was both well tolerated and produced clinical responses in COVID-19 patients.
  • Tiziana Life Sciencesis a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.

Global Rare Disease Genetic Testing Market Report 2022: Ongoing Conferences to Raise Awareness About Rare and Ultra-Rare Conditions to Boost Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, September 19, 2022
Research, Mental Health, Neurology, Genetics, Clinical Trials, Biotechnology, Health, Science, Oncology, Other Science, Health policy, Rare Disease Day, Neurology, Canadian Organization for Rare Disorders, National, Genetic testing, Adoption, Degenerative disease, Incidence, CORD, CVD, RDCRN, Sclerosis, Registry, Organization, Learning, Growth, Industry, Rare Diseases Clinical Research Network, Lists of diseases, USD, Patient, Investment, Cancer, Disorder, CLIA, Diagnosis, NGS, Research, Awareness, PCR, NIH, Disease, Disease management, CAGR, Vaccine, Pharmaceutical industry, Technology

The global rare disease genetic testing market size is expected to reach USD 2.52 billion by 2030, registering a CAGR of 13.94% over the forecast period, according to this report.

Key Points: 
  • The global rare disease genetic testing market size is expected to reach USD 2.52 billion by 2030, registering a CAGR of 13.94% over the forecast period, according to this report.
  • Effective regulatory plans to combat rare disease is one of the key drivers of the industry.
  • Ongoing conferences to raise awareness about rare and ultra-rare conditions are anticipated to boost the adoption of diagnostic kits and services.
  • Furthermore, the lack of awareness among patients and families about diagnosis and genetic testing has further impeded the industry's growth.

Global Optic Neuritis Treatment Market to Grow at a 4.1% CAGR Through 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 16, 2022
Optical, Health, COVID-19, Inflammation, Multiple sclerosis, Incidence, Journal, COVID-19, Woman, Optic neuritis, Brain, Prevalence, Sclerosis, Population, Journal of Neurologic Physical Therapy, Neuritis, Severe cognitive impairment, Eye, Steroid, Pain, Optic nerve, Awareness, Neurology, Color, Disease, Field line, CAGR, Telescopic sight, Dietary supplement, Medical imaging, Growth

The "Optic Neuritis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Optic Neuritis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The optic neuritis treatment market is expected to register a CAGR of 4.1% during the forecast period.
  • Rise in the geriatric population, increasing incidence of multiple sclerosis, and growing awareness about early detection of optic neuritis are the key driving factors of the optic neuritis treatment market.
  • According to the Optic Neuritis Foundation Inc, adults between the ages of 18-45 years are most prone to optic neuritis.

New Wahls Diet App Puts Health at the Fingertips of MS patients

Retrieved on: 
Thursday, September 8, 2022
Patient, University, LINCOLN, Food, Program, Disease, Multiple sclerosis, Meal, Health, Prognosis, Sclerosis, Wahls, Secondary, MS, Diabetes, Sugar, Functional medicine, Carbohydrate, Medical device, Dietary supplement, Medicine

LINCOLN, Neb., Sept. 8, 2022 /PRNewswire/ -- The software development company, Foogal, has just launched the Wahls Diet™ App, a program that removes the guesswork of searching for recipes to help patients feel their best. The smartphone technology gives users a carefully-designed roadmap to meet daily and weekly nutrition goals with delicious, anti-inflammatory food as medicine recipes recommended by leading medical expert in MS, Dr. Terry Wahls.

Key Points: 
  • "The Wahls Diet App can help you plan your family's meals to make sure your food choices are supporting your healing journey."
  • Dr. Wahls is living proof that a curated, nutrient-rich diet can reduce even some of the most debilitating MS symptoms when combined with a healthy lifestyle.
  • Now Dr. Wahls is working with Foogal to take the guesswork out of easing symptoms into remission for other MS patients.
  • "Together, working as one team, we developed a tool that will help Dr. Wahls' patients and followers embrace health and live their best lives."

The Multiple Sclerosis Association of America (MSAA) Launches Comprehensive Tool for the MS Community to Learn about Treatment Options

Retrieved on: 
Tuesday, August 16, 2022
FDA, Multimedia, Depression, CEO, MS, Sclerosis, CNS, Common, Clinical trial, Merck Serono, Brain, Helpline, Biogen, Learning, Multiple sclerosis, Prevalence, Communication, Research, Patient, Fatigue, MSAA, Motivator, View, Central nervous system, Blog, Safety, Ultimate, VP, Novartis, Spinal cord, Time, MRI, Cranial nerves, Bristol Myers Squibb, Medical device, Pharmaceutical industry, Online shopping, Genentech, Sanofi

CHERRY HILL, N.J., Aug. 16, 2022 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is proud to announce the launch of the Ultimate MS Treatment Guide – a unique and comprehensive tool to help people with multiple sclerosis learn about the different FDA-approved disease-modifying therapies. This online resource for the MS community, which can be accessed at www.MStreatmentguide.org, has been developed by MSAA in collaboration with Wondros, a global creative agency.

Key Points: 
  • CHERRY HILL, N.J., Aug. 16, 2022 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is proud to announce the launch of the Ultimate MS Treatment Guide a unique and comprehensive tool to help people with multiple sclerosis learn about the different FDA-approved disease-modifying therapies.
  • The Ultimate MS Treatment Guide is designed to provide the MS community with an easy-to-follow, step-by-step tool for understanding, comparing, and ultimately selecting the most appropriate disease-modifying treatment, in conjunction with one's physician.
  • MSAA's Ultimate MS Treatment Guide is an innovative tool that will be of tremendous assistance to both doctors and patients alike."
  • The Multiple Sclerosis Association of America (MSAA) is a national nonprofit organization and leading resource for the entire MS community, improving lives today through vital services and support.

TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022
FDA, U.S. Securities and Exchange Commission, Biologics license application, PDUFA, Risk, Trial of the century, Sclerosis, Food, GLOBE, European Academy of Management, R, Private Securities Litigation Reform Act, Clinical trial, Congress, Research, Annual report, Patient, Therapy, SG, COVID-19, Company, D, Acquisition, II, Finance, Prescription Drug User Fee Act, Ublituximab, NASDAQ, ARR, EAN, BLA, Food and Drug Administration, TG, Goal, Investor, LinkedIn, Conference, CMSC, Multiple sclerosis, Pharmaceutical industry, Video game, RMS

NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2022 and recent company developments, along with a business outlook for the remainder of 2022.

Key Points: 
  • NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2022 and recent company developments, along with a business outlook for the remainder of 2022.
  • The Company will host a conference call today, August 8, 2022, at 8:30 AM ET, to discuss the Companys second quarter 2022 financial results.
  • In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics.
  • Securities and Exchange Commission, including the most recent quarterly report on Form 10-Q for the second quarter ended June 30, 2022.

Global Multiple Sclerosis Therapeutics Market Analysis to 2029 - Featuring Teva Pharmaceuticals, Pfizer and Novartis Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 28, 2022
Health, Pharmaceutical, Administration, Therapy, CAGR, Multiple sclerosis, Region, Growth, Injection (medicine), Sclerosis, Disease, Mode, USD, Immunosuppressive drug, Pharmaceutical industry

The "Multiple Sclerosis Therapeutics Market Analysis by Drug Class (Immunosuppressant, Immunomodulators) By Mode of Administration (Injectable, Oral, Intravenous) and by Region - Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Multiple Sclerosis Therapeutics Market Analysis by Drug Class (Immunosuppressant, Immunomodulators) By Mode of Administration (Injectable, Oral, Intravenous) and by Region - Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The global multiple sclerosis therapeutics market size is estimated to be USD 27.84 billion in 2020 and is expected to witness a CAGR of 6.71% during the forecast period.
  • Increasing global prevalence of target disease is a key driver for the growth of the global multiple sclerosis therapeutics market.
  • Nevertheless, side-effects and risks associated with multiple sclerosis therapeutics and indeterminate etiology of the disease are expected to restrain the global market growth.